Literature DB >> 25930134

The clinical discovery of imipramine.

Walter A Brown1, Maria Rosdolsky.   

Abstract

The major classes of psychotropic drugs were introduced in an extraordinary decade of discovery between the late 1940s and late 1950s. In the present climate of pessimism about the absence of new drug development, it may be instructive to look back at the research methods used during that era. The study that identified the first antidepressant is a case in point. It was conducted by Roland Kuhn, a Swiss psychiatrist working in a remote psychiatric hospital. Kuhn, like the other pioneering researchers of his day, was given access to new drug entities, and the method he used to discover their clinical effects was open-minded, exploratory, comprehensive, clinical observation. The paper that reported the results of his study has not been available in English, but because of its historical significance and because Kuhn's achievement stands in such contrast to the present impasse in drug development, the authors thought that it might be informative to read about his discovery in his own words. Accordingly, one of the authors (M.R.) translated the paper into English, and they now present excerpts of that translation with the intent of encouraging reevaluation of contemporary approaches to drug discovery. By today's clinical research standards, Kuhn's method of unfettered, exploratory, clinical observation was substandard, haphazard, even messy. Yet it produced a major breakthrough-the discovery that a drug can alleviate depression-that has had a lasting impact on the treatment of depression and on the development of antidepressant drugs. Kuhn's experience might usefully inform our strategies of drug development.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25930134     DOI: 10.1176/appi.ajp.2015.14101336

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  9 in total

1.  The Intimate Geographies of Panic Disorder: Parsing Anxiety through Psychopharmacological Dissection.

Authors:  Felicity Callard
Journal:  Osiris       Date:  2016       Impact factor: 0.548

Review 2.  [Everyday transgressions of borderlines: the scandalization of clinical drug trials of the psychiatrist Roland Kuhn].

Authors:  Hanfried Helmchen
Journal:  Nervenarzt       Date:  2022-05-06       Impact factor: 1.214

Review 3.  Phenotypic drug discovery: recent successes, lessons learned and new directions.

Authors:  Fabien Vincent; Arsenio Nueda; Jonathan Lee; Monica Schenone; Marco Prunotto; Mark Mercola
Journal:  Nat Rev Drug Discov       Date:  2022-05-30       Impact factor: 112.288

Review 4.  Consistently Modest Antidepressant Effects in Clinical Trials: the Role of Regulatory Requirements.

Authors:  Arif Khan; Kaysee Fahl Mar; Walter A Brown
Journal:  Psychopharmacol Bull       Date:  2021-06-01

Review 5.  Monoaminergic and Histaminergic Strategies and Treatments in Brain Diseases.

Authors:  Giuseppe Di Giovanni; Dubravka Svob Strac; Montse Sole; Mercedes Unzeta; Keith F Tipton; Dorotea Mück-Šeler; Irene Bolea; Laura Della Corte; Matea Nikolac Perkovic; Nela Pivac; Ilse J Smolders; Anna Stasiak; Wieslawa A Fogel; Philippe De Deurwaerdère
Journal:  Front Neurosci       Date:  2016-11-24       Impact factor: 4.677

6.  Imipramine Protects against Bone Loss by Inhibition of Osteoblast-Derived Microvesicles.

Authors:  Lili Deng; Ying Peng; Yuhai Jiang; Yu Wu; Yuedi Ding; Yaping Wang; Dong Xu; Qiang Fu
Journal:  Int J Mol Sci       Date:  2017-05-08       Impact factor: 5.923

7.  Major Depressive Disorder and Kappa Opioid Receptor Antagonists.

Authors:  Wei Li; Huijiao Sun; Hao Chen; Xicheng Yang; Li Xiao; Renyu Liu; Liming Shao; Zhuibai Qiu
Journal:  Transl Perioper Pain Med       Date:  2016

Review 8.  The conundrum of depression clinical trials: one size does not fit all.

Authors:  Arif Khan; Kaysee Fahl Mar; Walter A Brown
Journal:  Int Clin Psychopharmacol       Date:  2018-09       Impact factor: 1.659

Review 9.  Blues in the Brain and Beyond: Molecular Bases of Major Depressive Disorder and Relative Pharmacological and Non-Pharmacological Treatments.

Authors:  Elisabetta Maffioletti; Alessandra Minelli; Daniela Tardito; Massimo Gennarelli
Journal:  Genes (Basel)       Date:  2020-09-18       Impact factor: 4.096

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.